- Home
- CSBR vs HLVX Comparison
CSBR vs HLVX Comparison
Compare CSBR & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- HLVX
- Stock Information
- Founded
- CSBR 1985
- HLVX 2020
- Country
- CSBR United States
- HLVX United States
- Employees
- CSBR N/A
- HLVX 90
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- CSBR Health Care
- HLVX Health Care
- Exchange
- CSBR Nasdaq
- HLVX Nasdaq
- Market Cap
- CSBR 98.1M
- HLVX 92.6M
- IPO Year
- CSBR 1986
- HLVX 2022
- Fundamental
- Price
- CSBR $7.55
- HLVX $1.86
- Analyst Decision
- CSBR Strong Buy
- HLVX Hold
- Analyst Count
- CSBR 1
- HLVX 5
- Target Price
- CSBR $8.00
- HLVX $2.33
- AVG Volume (30 Days)
- CSBR 61.8K
- HLVX 317.3K
- Earning Date
- CSBR 12-11-2024
- HLVX 11-07-2024
- Dividend Yield
- CSBR N/A
- HLVX N/A
- EPS Growth
- CSBR N/A
- HLVX N/A
- EPS
- CSBR N/A
- HLVX N/A
- Revenue
- CSBR $53,571,000.00
- HLVX N/A
- Revenue This Year
- CSBR $14.19
- HLVX N/A
- Revenue Next Year
- CSBR $10.11
- HLVX N/A
- P/E Ratio
- CSBR N/A
- HLVX N/A
- Revenue Growth
- CSBR 7.19
- HLVX N/A
- 52 Week Low
- CSBR $3.60
- HLVX $1.55
- 52 Week High
- CSBR $7.85
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- CSBR 71.57
- HLVX 44.78
- Support Level
- CSBR $4.61
- HLVX $1.95
- Resistance Level
- CSBR $7.85
- HLVX $1.97
- Average True Range (ATR)
- CSBR 0.75
- HLVX 0.07
- MACD
- CSBR 0.26
- HLVX -0.02
- Stochastic Oscillator
- CSBR 81.84
- HLVX 10.00
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.